Loges, Sonja.jpg

Associated Member since 04/21 | Project

Department of Personalized Oncology

Medical Faculty Mannheim, Heidelberg University

 

 

Sonja.Loges(at)medma.uni-heidelberg.de

Sonja Loges is a Professor at the Medical Faculty Mannheim of Heidelberg University, Chair of the Department of Personalized Oncology at the University Hospital Mannheim as well as Head of the Division Personalized Medical Oncology at the German Cancer Research Center in Heidelberg. She obtained her PhD in Biochemistry and Molecular Biology at the University of Hamburg and her MD at the University Medical Center Hamburg, worked as postdoctoral researcher at VIB-KU Leuven, Belgium and finished her residency at the University Medical Center, Hamburg, where she also worked as Professor in the Department of Hematology and Oncology and group leader in the Department of Hematology and Oncology and Institute of Tumor Biology.

Qualifications and Scientific Curriculum

1998-2004

Medical School with Medical Examination, University Medical Center Hamburg​

PhD in Biochemistry and Molecular Biology, University of Hamburg, Department of Biology

Dr. med., University Medical Center Hamburg

Resident, Department of Hematology and Oncology, University Medical Center Hamburg

Post-Doctoral Researcher, VIB-KU Leuven, Belgium

Assistant Professor (Habilitation)

Resident, Department of Hematology and Oncology, University Medical Center Hamburg

Junior Group Leader, Department of Hematology and Oncology, Institute of Tumor Biology, University Medical Center Hamburg

Attending Physician and Group Leader, Department of Hematology and Oncology & Institute of Tumor Biology, University Medical Center Hamburg

Leader of Thoracic Oncology and Personalized Oncology Programs,         Department of Hematology and Oncology, University Medical Center             Hamburg

W3 Heisenberg Professor, Department of Hematology and Oncology,        University Medical Center Hamburg

Full W3 Professor, Medical Faculty Mannheim, University of Heidelberg and Chair of the Department of Personalized Oncology, University Hospital Mannheim

Head of Division Personalized Medical Oncology, DKFZ, Heidelberg

Scientific Director Mannheim Cancer Center, Mannheim

2000-2004

2005

2005-2007

2007-2010

2012

2010-2014

2010-2015

2015-2020

2015-2020

2016-2020

since 2020

since 2020

since 2021

Selected publications

  1. Westphalen BC, Bokemeyer C, Büttner R, Fröhling S, Gaidzik VI, Glimm H, Hacker UT, Heinemann V, Illert AL, Keilholz U, Kindler T, Kirschner M, Schilling B, Siveke JT, Schroeder T, Tischler V, Wagner S, Weichert, Zips D, Loges S: Working Group Molecular Diagnostics and Therapy, Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. Eur J Cancer. 135:1-7, 2020.

  2. Carmeliet P, Li X, Treps L, Conradi LC*, Loges S*: RAISEing VEGF-D’s importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients. Ann Oncol. 29:527-529, 2018.

  3. Bauer R*, Udonta F*, Wroblewski M, Ben-Batalla I, Miranda Santos I, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner JM, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S: Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy. Cancer res. 78:3220-3232, 2018.

  4. Wroblewski M, Bauer R, Cubas Cordova M, Udonta F, Ben Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus JL, Schulze A, Pantel K, Bokemeyer C, Loges S: Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b. Nature Commun. 8:269, 2017.

  5. Ben Batalla I*, Erdmann R*, Jørgensen H*, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S: Axl Blockade by BGB324 inhibits BCR-Abl tyrosine kinase-sensitive and –resistant Chronic Myeloid Leukemia. Clin Cancer Res. 23:2289-2300, 2016.

  6. Waizenegger JS*, Ben-Batalla I*, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken C, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S: Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia. 29:696-704, 2015.

  7. Ben-Batalla I*, Schultze A*, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken C, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S: Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma. Blood. 122:2443-52, 2013.

  8. Schmidt T*, Masouleh BK*, Loges S*, Knevels E, Maes C, Jonckx B, de Keersmaecker K, Tjwa M, Schenk T, Kleppe M, Fragoso R, Beel K, DiasS, Verfaillie C, Clark RE, Brümmendorf TH, Vandenberghe T, Holyoake T, Hochhaus A, Rafii S, Karin M, Cools J, Carmeliet G, Carmeliet P: Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant BCR-ABL1+ leukemia. Cancer Cell. 19:740-53, 2011.

  9. Loges S, Mazzone M, Hohensinner P, Carmeliet P: Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 15:167-70, 2009.

  10. Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling M, Schuch G, Hossfeld DK, Fiedler W:. Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival. J Clin Oncol. 23:1109-17, 2005.